HAP Trading’s Apellis Pharmaceuticals APLS Stock Holding History

HAP Trading’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$11K	Hold	40,000	–	–	﹤0.01%	762
2025 Q2	$10K	Buy	+40,000	New	+$740K	﹤0.01%	653
2024 Q3	–	Sell	-193,300	Closed	-$78.8K	–	682
2024 Q2	$78.8K	Buy	+193,300	New	+$8.75M	0.01%	395
2024 Q1	–	Sell	-107,600	Closed	-$125K	–	711
2023 Q4	$125K	Buy	107,600 +100	+0.1%	+$5.07K	0.02%	341
2023 Q3	$41.7K	Buy	107,500 +7,500	+8%	+$329K	0.01%	539
2023 Q2	$1.2M	Sell	100,000 -21,300	-18%	-$1.84M	0.21%	100
2023 Q1	$263K	Sell	121,300 -18,700	-13%	-$1.08M	0.04%	270
2022 Q4	$832K	Buy	+140,000	New	+$7.43M	0.09%	208
2021 Q4	–	Sell	-69,500	Closed	-$2K	–	2510
2021 Q3	$2K	Buy	69,500 +53,700	+340%	+$3.02M	﹤0.01%	2292
2021 Q2	$241K	Buy	+15,800	New	+$815K	0.01%	934

Other funds holding APLS

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

HAP Trading's APLS Position: Q3 2025 in Review

HAP Trading increased its Apellis Pharmaceuticals (APLS) stake by 38% in Q3 2025, buying an estimated $159K and bringing the position to 24,763 shares worth $560K. The position accounts for 0.04% of the portfolio, ranked #246.

HAP Trading first reported a position in APLS in Q2 2024 and has held it in 3 quarters since. The position peaked at $2.49M in Q2 2024. 273 funds tracked by Wall St. Rank hold APLS as of Q3 2025.

HAP Trading held 24,763 shares of Apellis Pharmaceuticals worth $560K as of Q3 2025.
HAP Trading bought 6,826 Apellis Pharmaceuticals shares in Q3 2025, an estimated $159K.
Apellis Pharmaceuticals made up 0.04% of HAP Trading's portfolio in Q3 2025, its #246 holding.
HAP Trading first reported a position in Apellis Pharmaceuticals in Q2 2024 and has held it in 3 quarters since.
HAP Trading's Apellis Pharmaceuticals position peaked at $2.49M in Q2 2024.
273 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2025.

Based on HAP Trading's 13F filing for Q3 2025, filed 12 Nov 2025.